Cost-effectiveness Analysis of Radium-223 Dichloride in Metastatic Castration-Resistant Prostate Cancer Patients Without Previous Chemotherapy Treatment in Spain
**Purpose:** To perform a cost-effectiveness analysis of radium-223 plus Best Supportive Care (BSC) compared to BSC in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and without previous docetaxel treatment in Spain. **Design and methods:** A Markov model was...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Columbia Data Analytics, LLC
2018-01-01
|
| Series: | Journal of Health Economics and Outcomes Research |
| Online Access: | https://doi.org/10.36469/9777 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823860339018563584 |
|---|---|
| author | Eva Tirado Mercier Daniel Callejo Velasco Marta Rubio Cabezas Cristina Moretones Agut Meritxell Granell Villalón |
| author_facet | Eva Tirado Mercier Daniel Callejo Velasco Marta Rubio Cabezas Cristina Moretones Agut Meritxell Granell Villalón |
| author_sort | Eva Tirado Mercier |
| collection | DOAJ |
| description | **Purpose:** To perform a cost-effectiveness analysis of radium-223 plus Best Supportive Care (BSC) compared to BSC in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and without previous docetaxel treatment in Spain.
**Design and methods:** A Markov model was developed to compare radium-223 versus BSC and to accrue the health outcomes and costs of a simulated cohort of mCRPC patients. Quality-adjusted life year (QALY) and life year (LY) were selected as health outcomes to measure the effectiveness of treatment alternatives. Main health resource use and efficacy inputs were obtained from a randomized controlled trial comparing radium-223 versus placebo. Unit costs were retrieved from Spanish databases and published sources. One-way and probabilistic sensitivity analyses were carried out to assess uncertainty.
**Results:** Total costs and QALYs were €65 067 and 1.12 QALYs for radium-223 and €55 437 and 0.77 QALYs for BSC. Therefore, incremental costs per QALY were €27 606. The sensitivity analysis showed that with a willingness-to-pay threshold of €30 000 per QALY, radium-223 would have a probability of 48% of being cost-effective compared to BSC.
**Conclusions:** Although results must be assessed with caution, from the Spanish National Health System perspective and based on the results of the present analysis, radium-223 could be a suitable option of health resources’ utilization for end of life mCRPC without previous docetaxel treatment, subject to a moderate level of uncertainty. |
| format | Article |
| id | doaj-art-4c8e7f23d37549f4a9473ed6df793f23 |
| institution | Kabale University |
| issn | 2327-2236 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Columbia Data Analytics, LLC |
| record_format | Article |
| series | Journal of Health Economics and Outcomes Research |
| spelling | doaj-art-4c8e7f23d37549f4a9473ed6df793f232025-02-10T16:13:02ZengColumbia Data Analytics, LLCJournal of Health Economics and Outcomes Research2327-22362018-01-0161Cost-effectiveness Analysis of Radium-223 Dichloride in Metastatic Castration-Resistant Prostate Cancer Patients Without Previous Chemotherapy Treatment in SpainEva Tirado MercierDaniel Callejo VelascoMarta Rubio CabezasCristina Moretones AgutMeritxell Granell Villalón**Purpose:** To perform a cost-effectiveness analysis of radium-223 plus Best Supportive Care (BSC) compared to BSC in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and without previous docetaxel treatment in Spain. **Design and methods:** A Markov model was developed to compare radium-223 versus BSC and to accrue the health outcomes and costs of a simulated cohort of mCRPC patients. Quality-adjusted life year (QALY) and life year (LY) were selected as health outcomes to measure the effectiveness of treatment alternatives. Main health resource use and efficacy inputs were obtained from a randomized controlled trial comparing radium-223 versus placebo. Unit costs were retrieved from Spanish databases and published sources. One-way and probabilistic sensitivity analyses were carried out to assess uncertainty. **Results:** Total costs and QALYs were €65 067 and 1.12 QALYs for radium-223 and €55 437 and 0.77 QALYs for BSC. Therefore, incremental costs per QALY were €27 606. The sensitivity analysis showed that with a willingness-to-pay threshold of €30 000 per QALY, radium-223 would have a probability of 48% of being cost-effective compared to BSC. **Conclusions:** Although results must be assessed with caution, from the Spanish National Health System perspective and based on the results of the present analysis, radium-223 could be a suitable option of health resources’ utilization for end of life mCRPC without previous docetaxel treatment, subject to a moderate level of uncertainty.https://doi.org/10.36469/9777 |
| spellingShingle | Eva Tirado Mercier Daniel Callejo Velasco Marta Rubio Cabezas Cristina Moretones Agut Meritxell Granell Villalón Cost-effectiveness Analysis of Radium-223 Dichloride in Metastatic Castration-Resistant Prostate Cancer Patients Without Previous Chemotherapy Treatment in Spain Journal of Health Economics and Outcomes Research |
| title | Cost-effectiveness Analysis of Radium-223 Dichloride in Metastatic Castration-Resistant Prostate Cancer Patients Without Previous Chemotherapy Treatment in Spain |
| title_full | Cost-effectiveness Analysis of Radium-223 Dichloride in Metastatic Castration-Resistant Prostate Cancer Patients Without Previous Chemotherapy Treatment in Spain |
| title_fullStr | Cost-effectiveness Analysis of Radium-223 Dichloride in Metastatic Castration-Resistant Prostate Cancer Patients Without Previous Chemotherapy Treatment in Spain |
| title_full_unstemmed | Cost-effectiveness Analysis of Radium-223 Dichloride in Metastatic Castration-Resistant Prostate Cancer Patients Without Previous Chemotherapy Treatment in Spain |
| title_short | Cost-effectiveness Analysis of Radium-223 Dichloride in Metastatic Castration-Resistant Prostate Cancer Patients Without Previous Chemotherapy Treatment in Spain |
| title_sort | cost effectiveness analysis of radium 223 dichloride in metastatic castration resistant prostate cancer patients without previous chemotherapy treatment in spain |
| url | https://doi.org/10.36469/9777 |
| work_keys_str_mv | AT evatiradomercier costeffectivenessanalysisofradium223dichlorideinmetastaticcastrationresistantprostatecancerpatientswithoutpreviouschemotherapytreatmentinspain AT danielcallejovelasco costeffectivenessanalysisofradium223dichlorideinmetastaticcastrationresistantprostatecancerpatientswithoutpreviouschemotherapytreatmentinspain AT martarubiocabezas costeffectivenessanalysisofradium223dichlorideinmetastaticcastrationresistantprostatecancerpatientswithoutpreviouschemotherapytreatmentinspain AT cristinamoretonesagut costeffectivenessanalysisofradium223dichlorideinmetastaticcastrationresistantprostatecancerpatientswithoutpreviouschemotherapytreatmentinspain AT meritxellgranellvillalon costeffectivenessanalysisofradium223dichlorideinmetastaticcastrationresistantprostatecancerpatientswithoutpreviouschemotherapytreatmentinspain |